Urticaria clinical trials

Explore recruiting urticaria clinical trials.

Recruiting urticaria studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Urticaria trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines

Romania, Slovakia, Poland, Portugal, France, Hungary +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants from Jasper-Sponsored Chronic Urticaria Trials

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled by H1-antihistamines followed by an optional open-label extension for up to another 3 years and an optional safety long-term treatment-free follow-up period for up to an additional 3 years.

Poland, Germany, Spain, Netherlands, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ – CSU2)

Bulgaria, Spain, Hungary, Slovakia, Italy, Netherlands +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

COURAGE - Corticosteroid in acute urticaria in emergency department

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Proof of concept study to assess the efficacy and safety of Danicopan (factor D inhibitor) in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment (DANICSU).

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Urticaria trials by city

Urticaria in Toronto Urticaria in Vancouver Urticaria in Montreal Urticaria in Calgary Urticaria in Edmonton Urticaria in Ottawa Urticaria in Winnipeg Urticaria in Quebec City Urticaria in Hamilton Urticaria in Kitchener Urticaria in London Urticaria in Halifax Urticaria in New York Urticaria in Los Angeles Urticaria in Chicago Urticaria in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease